The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Join NJ ACTS Biostatistics, Epidemiology, Research Design (BERD) on 4/24 at 1pm for a Workshop
- Rutgers Health Researchers Reveal Health Care Disparities for People with Disabilities.
- Rutgers Researchers Revive Decades-Old Pregnancy Cohort with Modern Scientific Potential.
- Rutgers Researchers Revive Decades-Old Pregnancy Cohort with Modern Scientific Potential.
- Hidden in Plain Sight: The Chemical Burden of Personal Care Products.
Categories
- Community (2,197)
- Covid (983)
- CTO Events (6)
- News (2,805)
- Pilots (21)